Effect of the p53α gene on the chemosensitivity of the H1299 human lung adenocarcinoma cell line

Liu,Kaishan; Gao,Weisong; Lin,Jun

doi:10.3892/ol.2017.6356

Effect of the p53α gene on the chemosensitivity of the H1299 human lung adenocarcinoma cell line

Authors:
- Kaishan Liu
- Weisong Gao
- Jun Lin
View Affiliations

Affiliations: Department of Pathology, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, P.R. China
Published online on: June 8, 2017 https://doi.org/10.3892/ol.2017.6356
Pages: 1411-1418
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To investigate the effects of tumor protein p53 (p53 or TP53) α gene on the chemosensitivity of the H1299 human lung adenocarcinoma cell line, the recombinant vector pEGFP‑p53α was constructed. The vector pEGFP‑p53α was transfected into the cultured p53‑null H1299 cells using Lipofectamine 2000. The G418‑resistant cells were then selected. The expression of the p53α gene in these cells was examined using reverse transcription‑polymerase chain reaction, and TP53 protein expression was examined using western blot analysis and immunocytochemistry. An MTT assay and colony formation assay were used to analyze the response of the transfected cells to cisplatin (CDDP). DAPI staining was used to determine the level of apoptosis of the transfected cells. The transfected H1299 human lung adenocarcinoma cells stably expressed TP53 protein. The MTT assay demonstrated that the 50% inhibitory concentrations for the H1299, H1299/pEGFP‑N1 and H1299/pEGFP‑p53α cells were 28, 24 and 18 µmol/l, respectively. The survival rate of H1299/pEGFP‑p53α cells was significantly reduced compared with that of H1299 and H1299/pEGFP‑N1 cells (P<0.05). The colony formation assay and DAPI staining identified that the colony formation rate and the number of apoptotic cells of H1299/pEGFP‑p53α were significantly reduced, compared with those of the H1299 and H1299/pEGFP‑N1 cells (P<0.05). Therefor, the present study demonstrated that the transfection of H1299 cells with the p53α gene resulted in an increase in sensitivity to CDDP chemotherapy. The combination of CDDP and gene therapy for H1299 lung adenocarcinoma cell line provides an experimental basis for clinical research.

View Figures

View References

1	Shao C, Lu C, Chen L, Koty PP, Cobos E and Gao W: p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother Pharmacol. 67:1369–1380. 2011. View Article : Google Scholar : PubMed/NCBI
2	Monroy-Estrada HI, Chirino YI, Soria-Mercado IE and Sánchez-Rodríguez J: Toxins from the Caribbean sea anemone Bunodeopsis globulifera increase cisplatin-induced cytotoxicity of lung adenocarcinoma cells. J Venom Anim Toxins Incl Trop Dis. 19:122013. View Article : Google Scholar : PubMed/NCBI
3	Ning X, Sun Z, Wang Y, Zhou J, Chen S, Chen D and Zhang H: Docetaxel plus trans-tracheal injection of adenoviral-mediated p53 versus docetaxel alone in patients with previously treated non-small-cell lung cancer. Cancer Gene Ther. 18:444–449. 2011. View Article : Google Scholar : PubMed/NCBI
4	Al-Taweel N, Varghese E, Florea A and Büsselberg D: Cisplatin (CDDP) triggers cell death of MCF-7 cells following disruption of intracellular calcium ([Ca (2+)]i) homeostasis. J Toxicol Sci. 39:765–774. 2014. View Article : Google Scholar : PubMed/NCBI
5	Saha MN, Qiu L and Chang H: Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol. 6:232013. View Article : Google Scholar : PubMed/NCBI
6	Guan YS, Liu Y, Zou Q, He Q, La Z, Yang L and Hu Y: Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up. J Zhejiang Univ Sci B. 10:331–340. 2009. View Article : Google Scholar : PubMed/NCBI
7	Ma JT, Han CB, Zhao JZ, Jing W, Zhou Y, Huang LT and Zou HW: Synergistic cytotoxic effects of recombinant human adenovirus p53 and radiation at various time points in A549 lung adenocarcinoma cells. Oncol Lett. 4:529–533. 2012.PubMed/NCBI
8	Pietsch EC, Sykes SM, McMahon SB and Murphy ME: The p53 family and programmed cell death. Oncogene. 27:6507–6521. 2008. View Article : Google Scholar : PubMed/NCBI
9	Selivanova G: Therapeutic targeting of p53 by small molecules. Semin Cancer Biol. 20:46–56. 2010. View Article : Google Scholar : PubMed/NCBI
10	Rousseau B, Jacquot C, Le Palabe J, Malleter M, Tomasoni C, Boutard T, Sakanyan V and Roussakis C: TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: Potential targets in non-small cell lung cancer treatment. Sci Rep. 5:103562015. View Article : Google Scholar : PubMed/NCBI
11	Muller PA and Vousden KH: p53 mutations in cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
12	Liu X, Lin XJ, Wang CP, Yan KK, Zhao LY, An WX and Liu XD: Association between smoking and p53 mutation in lung cancer: A meta-analysis. Clin Oncol (R Coll Radiol). 26:18–24. 2014. View Article : Google Scholar : PubMed/NCBI
13	Zhao J, Lu Y and Shen HM: Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells. Cancer Lett. 314:8–23. 2012. View Article : Google Scholar : PubMed/NCBI
14	Vaughan CA, Frum R, Pearsall I, Singh S, Windle B, Yeudall A, Deb SP and Deb S: Allele specific gain-of-function activity of P53 mutants in lung cancer cells. Biochem Biophys Res Commun. 428:6–10. 2012. View Article : Google Scholar : PubMed/NCBI
15	Gibbons DL, Byers LA and Kurie JM: Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 12:3–13. 2014. View Article : Google Scholar : PubMed/NCBI
16	Mattioni M, Soddu S, Prodosmo A, Visca P, Conti S, Alessandrini G, Facciolo F and Strigari L: Prognostic role of serum p53 antibodies in lung cancer. BMC cancer. 15:1482015. View Article : Google Scholar : PubMed/NCBI
17	Machado-Silva A, Perrier S and Bourdon JC: p53 family members in cancer diagnosis and treatment. Semin Cancer Biol. 20:57–62. 2010. View Article : Google Scholar : PubMed/NCBI
18	Mogi A and Kuwano H: TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol. 2011:5839292011. View Article : Google Scholar : PubMed/NCBI
19	Muller PA and Vousden KH: Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
20	Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 303:844–848. 2004. View Article : Google Scholar : PubMed/NCBI
21	Yu X, Narayanan S, Vazquez A and Carpizo DR: Small molecule compounds targeting the p53 pathway: Are we finally making progress? Apoptosis. 19:1055–1068. 2014. View Article : Google Scholar : PubMed/NCBI
22	Yu M, Chen W and Zhang J: p53 gene therapy for pulmonary metastasis tumor from hepatocellular carcinoma. Anticancer Drugs. 21:882–884. 2010. View Article : Google Scholar : PubMed/NCBI
23	Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D and Gallagher WM: p53 as a target for the treatment of cancer. Cancer Treat Rev. 40:1153–1160. 2014. View Article : Google Scholar : PubMed/NCBI
24	Zhang Y, Zhang Q, Zeng SX, Hao Q and Lu H: Inauhzin sensitizes p53-dependent cytotoxicity and tumor suppression of chemotherapeutic agents. Neoplasia. 15:523–534. 2013. View Article : Google Scholar : PubMed/NCBI